Literature DB >> 17909564

Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.

Y Zhu1, D W Hein.   

Abstract

Genetic variants of human N-acetyltransferase 1 (NAT1) are associated with cancer and birth defects. N- and O-acetyltransferase catalytic activities, Michaelis-Menten kinetic constants (K(m) and V(max)) and steady-state expression levels of NAT1-specific mRNA and protein were determined for the reference NAT1*4 and variant human NAT1 haplotypes possessing single nucleotide polymorphisms (SNPs) in the open reading frame. Although none of the SNPs caused a significant effect on steady-state levels of NAT1-specific mRNA, C97T(R33stop), C190T(R64W), C559T (R187stop) and A752T(D251V) each reduced NAT1 protein level and/or N- and O-acetyltransferase catalytic activities to levels below detection. G560A(R187Q) substantially reduced NAT1 protein level and catalytic activities and increased substrate K(m). The G445A(V149I), G459A(synonymous) and T640G(S214A) haplotype present in NAT1*11 significantly (P<0.05) increased NAT1 protein level and catalytic activity. Neither T21G(synonymous), T402C(synonymous), A613G(M205V), T777C(synonymous), G781A(E261K) nor A787G(I263V) significantly affected K(m), catalytic activity, mRNA or protein level. These results suggest heterogeneity among slow NAT1 acetylator phenotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909564      PMCID: PMC2575040          DOI: 10.1038/sj.tpj.6500483

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  33 in total

Review 1.  Arylamine N-acetyltransferases: what we learn from genes and genomes.

Authors:  Sotiria Boukouvala; Giannoulis Fakis
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

2.  Single-nucleotide polymorphisms can cause different structural folds of mRNA.

Authors:  L X Shen; J P Basilion; V P Stanton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

3.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

Authors:  Danxin Wang; Andrew D Johnson; Audrey C Papp; Deanna L Kroetz; Wolfgang Sadée
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

4.  The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida.

Authors:  Liselotte E Jensen; Katy Hoess; Alexander S Whitehead; Laura E Mitchell
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2005-07

5.  Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse.

Authors:  M A Leff; P N Epstein; M A Doll; A J Fretland; U S Devanaboyina; T D Rustan; D W Hein
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe.

Authors:  N C Hughes; S A Janezic; K L McQueen; M A Jewett; T Castranio; D A Bell; D M Grant
Journal:  Pharmacogenetics       Date:  1998-02

7.  The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation.

Authors:  Yu Zang; Shuang Zhao; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenetics       Date:  2004-11

8.  Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts.

Authors:  Edward J Lammer; Gary M Shaw; David M Iovannisci; Richard H Finnell
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2004-11

9.  Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.

Authors:  H J Lin; N M Probst-Hensch; N C Hughes; G T Sakamoto; A D Louie; I H Kau; B K Lin; D B Lee; J Lin; H D Frankl; E R Lee; S Hardy; D M Grant; R W Haile
Journal:  Pharmacogenetics       Date:  1998-06

Review 10.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  16 in total

1.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

2.  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Authors:  Danxin Wang; Michael F Para; Susan L Koletar; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

3.  Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Authors:  Yuanqi Zhu; J Christopher States; Yang Wang; David W Hein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-02-02

Review 4.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

5.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021

Review 6.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

7.  Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk.

Authors:  Aesun Shin; Martha J Shrubsole; Jeffrey M Rice; Qiuyin Cai; Mark A Doll; Jirong Long; Walter E Smalley; Yu Shyr; Rashmi Sinha; Reid M Ness; David W Hein; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

Review 8.  Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review.

Authors:  David W Hein; Giannoulis Fakis; Sotiria Boukouvala
Journal:  Pharmacogenet Genomics       Date:  2018-10       Impact factor: 2.089

Review 9.  Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.

Authors:  Jason M Walraven; John O Trent; David W Hein
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

10.  Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.

Authors:  Carmine S Leggett; Mark A Doll; J Christopher States; David W Hein
Journal:  Arch Toxicol       Date:  2020-11-02       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.